SynCore Biotechnology (Taiwan) Today
| 4192 Stock | TWD 36.40 0.10 0.28% |
Performance0 of 100
| Odds Of DistressLess than 22
|
SynCore Biotechnology is selling for under 36.40 as of the 26th of November 2024; that is 0.28 percent increase since the beginning of the trading day. The stock's lowest day price was 36.4. SynCore Biotechnology has about a 22 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for SynCore Biotechnology Co are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 27th of October 2024 and ending today, the 26th of November 2024. Click here to learn more.
,Ltd, a biopharmaceutical company, engages in the research and development, manufacture, and marketing of drugs in the areas of oncology, ophthalmology, dermatology, and infectious diseases in Taiwan and internationally. The company was founded in 2008 and is headquartered in Yilan, Taiwan. The company has 115.08 M outstanding shares. More on SynCore Biotechnology Co
Moving together with SynCore Stock
| 0.86 | 4743 | Oneness Biotech | PairCorr |
| 0.89 | 6547 | Medigen Vaccine Biologics | PairCorr |
| 0.83 | 4174 | OBI Pharma | PairCorr |
Moving against SynCore Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
SynCore Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. SynCore Biotechnology's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding SynCore Biotechnology or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Chairman of the Board | ChihWen Lee |
| Thematic Idea | Biotech (View all Themes) |
| Business Concentration | Biotech, Biotechnology, Healthcare (View all Sectors) |
SynCore Biotechnology Co (4192) is traded on Taiwan OTC Exchange in Taiwan and employs 65 people. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.88 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate SynCore Biotechnology's market, we take the total number of its shares issued and multiply it by SynCore Biotechnology's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. SynCore Biotechnology operates under Healthcare sector and is part of Biotechnology industry. The entity has 115.08 M outstanding shares.
SynCore Biotechnology Co has accumulated about 380.81 M in cash with (229.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.57.
Check SynCore Biotechnology Probability Of Bankruptcy
Ownership AllocationSynCore Biotechnology shows a total of 115.08 Million outstanding shares. SynCore Biotechnology has majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 66.92 % of SynCore Biotechnology outstanding shares that are owned by insiders indicates they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check SynCore Ownership Details
SynCore Biotechnology Risk Profiles
Although SynCore Biotechnology's alpha and beta are two of the key measurements used to evaluate SynCore Biotechnology's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 0.9263 | |||
| Standard Deviation | 1.34 | |||
| Variance | 1.79 | |||
| Risk Adjusted Performance | (0.06) |
SynCore Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in SynCore Biotechnology without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run ETFs Now
ETFsFind actively traded Exchange Traded Funds (ETF) from around the world |
| All Next | Launch Module |
SynCore Biotechnology Corporate Management
Elected by the shareholders, the SynCore Biotechnology's board of directors comprises two types of representatives: SynCore Biotechnology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of SynCore. The board's role is to monitor SynCore Biotechnology's management team and ensure that shareholders' interests are well served. SynCore Biotechnology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, SynCore Biotechnology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| ChiaHao Liang | Senior Manager of Finance & Accounting | Profile | |
| MuhHwan Su | General Manager | Profile | |
| WenHsin Huang | VP Department | Profile | |
| FernFang Lin | VP Devel | Profile | |
| CharnJung Chang | General Manager-Ophthalmology Project | Profile | |
| HuiHung MBA | VP Drugs | Profile |
Additional Tools for SynCore Stock Analysis
When running SynCore Biotechnology's price analysis, check to measure SynCore Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SynCore Biotechnology is operating at the current time. Most of SynCore Biotechnology's value examination focuses on studying past and present price action to predict the probability of SynCore Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SynCore Biotechnology's price. Additionally, you may evaluate how the addition of SynCore Biotechnology to your portfolios can decrease your overall portfolio volatility.